Identification of GLUT12/SLC2A12 as a urate transporter that regulates the blood urate level in hyperuricemia model mice

Yu Toyoda1,2, Tappei Takada1,2, Hiroshi Miyata1, Hirotaka Matsuo3, Hidetoshi Kassai4, Kazuki Nakao5, Masahiro Nakatoh6, Yusuke Kawamura7, Seiko Shimizu8, Nariyoshi Shinomiya9, Kimiyoshi Ichida10, Makoto Hosoyamada11, Atsu Aiba12, and Hiroshi Suzuki13

1Department of Pharmacy, The University of Tokyo Hospital, Bunkyo-ku, 113-8655 Tokyo, Japan; 2Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, 359-8513 Saitama, Japan; 3Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, 113-0033 Tokyo, Japan; 4Division of Public Health Informatics, Department of Integrative Health Science, Nagoya University Graduate School of Medicine, 461-8673 Nagoya, Japan; 5Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, 192-0392 Tokyo, Japan; and 6Department of Human Physiology and Pathology, Faculty of Pharma-Sciences, Teikyo University, Itabashi-ku, 173-8605 Tokyo, Japan

Edited by Francisco Bezanilla, The University of Chicago, Chicago, IL, and approved June 29, 2020 (received for review April 14, 2020)

Recent genome-wide association studies have revealed some genetic loci associated with serum uric acid levels and susceptibility to gout/hyperuricemia which contain potential candidates of physiologically important urate transporters. One of these novel loci is located upstream of SGK1 and SLC2A12, suggesting that variations in these genes increase the risks of hyperuricemia and gout. We herein focused on SLC2A12 encoding a transporter, GLUT12, the physiological function of which remains unclear. As GLUT12 belongs to the same protein family as a well-recognized urate transporter GLUT9, we hypothesized that GLUT12 mediates membrane transport of urate. Therefore, we conducted functional assays and analyzed Glut12 knockout model mice, generated using the CRISPR-Cas9 system. Our results revealed that GLUT12 acts as a physiological urate transporter and its dysfunction elevates the blood urate concentration. This study provides insights into the deeper understanding of the urate regulatory system in the body, which is also important for pathophysiology of gout/hyperuricemia.

Genes encoding physiologically important urate transporters have been reportedly associated with serum uric acid (SUA) levels and susceptibility to gout/hyperuricemia (1). A previous study has reported a novel locus for SUA on human chromosome 6 near the SGK1 and SLC2A12 genes (2), which is consistent with the result derived from our previous genetic study (3). As SGK1 encodes a kinase protein, we focused on SLC2A12 encoding a transporter protein known as GLUT12, whose physiological function remains unclear. Since GLUT12 belongs to the same protein family as GLUT9/SLC2A9 [a physiologically important urate transporter (4)], we hypothesized that GLUT12 regulates blood urate concentrations as a urate transporter. To verify this hypothesis, we conducted functional assays and analyzed newly generated Glut12 knockout (KO) hyperuricemia model mice.

First, using mammalian cells transiently expressing GLUT12, we examined whether GLUT12 can transport urate. After confirming the cellular expression and plasma membrane localization of GLUT12 (Fig. 1A and B), we measured the amount of [8,14C]urate incorporated into the cells (Fig. 1C). In Krebs buffer mimicking the ionic content of plasma, GLUT12-mediated urate transport was detected. Neither exclusion of sodium from the Krebs buffer nor a high-potassium buffer condition that depolarizes plasma membranes affected GLUT12-mediated urate uptake, indicating that GLUT12 is a sodium-independent and bidirectional urate transporter. Additionally, an enhanced green fluorescent protein (EGFP) tag hardly affected the urate transport activity of GLUT12 (Fig. 1D); GLUT12 is more active at lower pH (Fig. 1E). As GLUT12-mediated urate uptake increased linearly with time over 10 min (Fig. 1F), uptake at 5 min was evaluated in subsequent kinetic analysis. Under the experimentally maximum urate concentration (500 μM), GLUT12-mediated urate uptake was not saturable (Fig. 1G). Considering urate concentrations in the blood of healthy (nonhyperuricemia) subjects (<0.41 mmol/L: 6.8 mg/dL) (1), our results suggest that GLUT12 can physiologically maintain urate transport activity in humans. With mouse Glut12, similar results were obtained (Fig. 1 H–J).

Next, to address the physiological impact of Glut12 on blood urate concentrations, we analyzed Glut12 KO mice. Notably, urate is degraded in wild-type mice owing to urate oxidase (Uox), which humans lack. Therefore, we generated two lines of Glut12 KO mice on Uox KO background (5), as Uox KO mice spontaneously develop hyperuricemia. The established Glut12/1/Oux double-KO (DKO) lines had deletions causing a frameshift in Glut12 (Fig. 1K). Each frameshift mutation disrupted the Glut12 urate transport function (Fig. 1L), indicating that the DKO lines were deficient in Glut12 function. Then, we examined plasma parameters; urate concentrations in both DKO mouse lines were higher than those in control Uox KO mice (Fig. 1M), which strongly supported our hypothesis. However, Glut12 KO did not affect the plasma creatinine concentration (Fig. 1N) and fractional renal urate excretion in each DKO line (Fig. 1O), suggesting that Glut12 deficiency does not induce severe renal dysfunction or decrease renal urate excretion. Moreover, hepatic urate levels in the DKO mice tended to be lower than those in control mice (Fig. 1P), suggesting that the Glut12 deficiency-dependent elevation of the blood urate concentration is not due to overproduction of uric acid in the liver. However, importantly, the significantly lower values of the liver-to-plasma urate concentration ratio in the DKO mice (Fig. 1Q) implied that Glut12 might be involved in urate transport from the blood into the liver. These findings are in line with gene expression
Fig. 1. GLUT12/SLC2A12 is a urate transporter, genetic disruption of which affects the blood urate concentration in genetically induced hyperuricemia model mice. (A–J) Identification of human GLUT12 and mouse Glut12 as a novel urate transporter. Immunoblotting (A) and confocal microscopic observation (B) of GLUT12 transiently expressed in HEK293 cells. Magnified images of representative cells outlined by yellow squares are also shown. (Scale bars, 10 μm.) Urate transport activities of GLUT12 in various transport buffers (C). EGFP tag barely affects the urate transport activity of GLUT12 (D). White, mock; black, GLUT12. Acidic pH-dependent [3H]urate transport activities of GLUT12 (E) and Glut12 (H). Time profiles for GLUT12- (F) or Glut12- (I) mediated [3H]urate uptake into HEK293 cells. Unsaturated GLUT12- (G) or Glut12- (J) mediated [3H]urate transport activities with increasing urate concentrations. In E–J, Krebs–Ringer buffer (pH 5.4) was used. (K–Q) Physiological impact of Glut12 KO on blood urate concentrations in hyperuricemia model mice. Schematic illustration of disrupted Glut12 gene in each Glut12urate oxidase (Uox) DKO line: #1, Glut12ΔΔ; #2, Glut12ΔΔΔ (K). Glut12 KO mutants transiently expressed in HEK293 cells exhibit no urate transport activity in Krebs–Ringer buffer (pH 5.4) (L). Plasma urate concentrations are significantly higher in Glut12/Uox DKO mice than in Uox KO mice (Glut12 wild-type [WT]; control) (M). Plasma creatinine concentration (N) and fractional renal urate excretion (FECr, urate clearance/creatinine clearance ratio) (O) do not significantly differ; n = 22 (WT), 7 (#1), and 13 (#2). The hepatic urate level tends to be lower (P) and the liver-to-plasma urate concentration ratios are significantly lower (Q) in Glut12/Uox DKO mice than in Uox KO mice; n = 4. Data are expressed as the mean ± SD, n = 3 (C–J and L) or the mean ± SEM (M–Q). *P < 0.05; **P < 0.01 (two-sided t test). *P < 0.05; **P < 0.01 vs. control; NS, not significantly different among groups (Dunnett’s test).

In summary, we successfully identified GLUT12 as a urate transporter, dysfunction of which elevates the blood urate concentration. Further investigation of the long-term effects of this phenotype on whole-body health including lifespan is warranted. Our findings deepen the understanding of the urate regulatory system in the body, which is also important for pathophysiology of gout/hyperuricemia.

data published in RefEx (6) showing that GLUT12/Glut12 is expressed relatively ubiquitously, including in the liver.
Materials and Methods
All animals received humane care according to criteria outlined in the Guide for the Care and Use of Laboratory Animals (7). All animal experiments were performed according to methods approved by the Institutional Animal Care and Use Committee of the University of Tokyo. All animals were maintained as described previously (8). Uox KO mice with a C57BL/6J genetic background, originally obtained from The Jackson Laboratory (stock no.: 002223, B6;129S7-Uox<sup>tm1Bay</sup>/J), were from our previous study (9). Mice with the Uox<sup>−/−</sup> background were administered 180 mg/L allopurinol (Wako Pure Chemical Industries) and 4 g/L Uralyt-U (a standardized mixture of potassium citrate and sodium citrate; Nippon Chemiphar) via drinking water to attenuate hyperuricemia phenotypes that cause serious kidney injury and premature death phenotype (5, 10).

Glut12<sup>−/−</sup>Uox<sup>−/−</sup> DKO mice were generated using the CRISPR-Cas9 system (11), using wild-type eggs and Uox<sup>−/−</sup> KO sperm. After crossing of mice, we designated mice with homozygous Glut 8del; Uoxtm1Bay and Glut128del; Uoxtm1Bay alleles as Glut12/Uox DKO #1 and Glut12/Uox DKO #2, respectively. These two alleles had 8 and 128 base deletions in exon 2 of Glut12, and both mutations caused a frameshift. Functional analyses and experimental measurements were conducted according to our previous studies (8, 9, 12).

Data Availability. All relevant data are within the paper.

ACKNOWLEDGMENTS. We thank Dr. Ryoko Kudo for her technical support with developmental engineering. This study was supported by Japan Society for the Promotion of Science KAKENHI (grants 16H01808 and 20H00568 to T.T.); T.T. has received research grants from the Gout and Uric Acid Foundation of Japan, Takeda Science Foundation, Suzuken Memorial Foundation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research.

1. N. Dalbeth et al., Gout. Nat. Rev. Dis. Primers 5, 69 (2019).
2. A. Tin et al.; CARe and CHARGE Consortia, Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum. Mol. Genet. 20, 4056–4068 (2011).
3. M. Nakatochi et al., Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Commun. Biol. 2, 115 (2019).
4. H. Matsuo et al., Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am. J. Hum. Genet. 83, 744–751 (2008).
5. X. Wu et al., Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 91, 742–746 (1994).
6. H. Ono, O. Ogawara, K. Okubo, H. Bono, RefEx, a reference gene expression dataset as a web tool for the functional analysis of genes. Sci. Data 4, 170105 (2017).
7. National Research Council, Guide for the Care and Use of Laboratory Animals, (National Academies Press, Washington, DC, 8th Ed., 2011).
8. T. Takada et al., Identification of ABCG2 as an exporter of uremic toxin indoxyl sulfate in mice and as a crucial factor influencing CKD progression. Sci. Rep. 8, 11147 (2018).
9. T. Watanabe et al., The mechanism of false in vitro elevation of uric acid level in mouse blood. Biol. Pharm. Bull. 39, 1081–1084 (2016).
10. J. Lu et al., Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 93, 69–80 (2018).
11. H. Nakao et al., A possible aid in targeted insertion of large DNA elements by CRISPR/Cas in mouse zygotes. Genesis 54, 65–77 (2016).
12. Y. Toyoda et al., Inhibitory effect of Citrus flavonoids on the in vitro transport activity of human urate transporter 1 (URAT1/SLC22A12), a renal re-absorber of urate. Nutr. Sci. Food 4, 3 (2020).